Follow the Prostatype Genomics AB share price and the full management transaction log of the company, a publicly traded company based in Finland. Shares are quoted on the FI market, under the supervision of FIN-FSA. Operating in the Health Care sector, Prostatype Genomics AB has recorded 9 insider filings. Market capitalisation: €15.2m. The latest transaction was disclosed on 15 August 2026 (Purchase). Among the most active insiders: Michael Häggman. The full history is accessible without an account.
9
Insider Decl.
n/a
Thresholds
€413,131
9 ops.
Buy Volume
n/a
n/a
Sell Volume
41Σ signal
Buys €413,131n/a Sells
Fundamental score
Ranked 25,209 of 29,063 companies
25.2
score / 100
Value
0
Quality
50
FCF yld-160%
Earn yld-191%
EV/EBITDA·
ROE-148%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
175,000 shares@ €0.36540.15% mcap100.0% of flowBTU (betald tecknad unit)ISINISIN SE0024990089FI:A003P469-1
9 of 9 declarations
Acerca de Prostatype Genomics AB
Prostatype Genomics AB es una empresa centrada en el desarrollo de pruebas genómicas para el cáncer de próstata. Cotiza en la Bolsa de Estocolmo (XSTO).